Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q2 2023 Earnings Report

bioAffinity Technologies logo
$0.27 -0.03 (-10.82%)
As of 01:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$19.74 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Monday, August 14, 2023
Conference Call Time
8:00AM ET

Upcoming Earnings

bioAffinity Technologies' Q2 2025 earnings is scheduled for Tuesday, August 12, 2025, with a conference call scheduled on Wednesday, August 13, 2025 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

bioAffinity Technologies Earnings Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat